Intercept Pharma (NASDAQ:ICPT) reported Q2 EPS of ($0.25), $0.21 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $71.76 million versus the consensus estimate of $95.98 million.
GUIDANCE:
Intercept Pharma sees FY2022 revenue of $325-345 million, versus the consensus of $386.2 million.